Patent Application
20080095857
To prepare nanoparticles according to the present invention, an aqueous gelatine solution was converted, by a double desolvation procedure, to nanoparticles, and the latter were subsequently stabilized by crosslinking. The functional groups (amino groups, carboxyl groups, hydroxyl groups) located on the surface of these nanoparticles can be converted to reactive thiol groups by suitable reagents. Functional proteins can be bound to these thiol group-modified nanoparticles by bifunctional spacer molecules which are reactive both to amino groups and to free thiol groups. These functional proteins include, in particular, avidin derivatives or cell-specific antibodies.
When preparing the nanoparticles for the cell culture tests described hereinbelow, the primary amino groups on the particle surface were reacted with 2-iminothiolane, which resulted in the introduction of free thiol groups on the particle surface. The amino groups of the avidin derivative NeutrAvidin® were activated with the bifunctional spacer Sulfo-MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester), and after column-chromatographic purification of this activation intermediate stage the thiolated gelatine nanoparticles were added thereto. This intermediate product of the avidin-modified nanoparticles represents a universal carrier system for a variety of biotinylated substances which can be bound via the avidin-biotin complex formation.
For bonding of the antibodies, preferably of monoclonal antibodies, the antibodies were either purchased in biotinylated form, or they were biotinylated by conversion with NHS biotin (N-hydroxysuccinimidobiotin), and the avidin-modified nanoparticles were added thereto. Thereby, antibody-modified nanoparticles based on gelatine were obtained via the above-described avidin-biotin complex formation (
The present invention thus comprises a carrier system for the cell-specific, intracellular enrichment of at least one pharmacologically active substance, which carrier system is present in the form of protein-based nanoparticles and comprises structures that are coupled by reactive groups, said structures enabling a cell-specific attachment and cellular absorption of the nanoparticles. Gelatine and/or serum albumin, especially preferably human serum albumin, are preferably taken into consideration as the protein basis. The reactive group preferably is an amino, thiol, carboxyl group, or an avidin derivative, and the coupled structure is an antibody, especially preferably a monoclonal antibody.
The invention also encompasses a corresponding carrier system which additionally contains at least one pharmaceutically active substance that is bound by adsorption, incorporation or covalent or complexing bonds to the carrier system or nanoparticles by the reactive groups.
The invention further encompasses the use of a carrier system according to the invention for producing a medicament for enrichment of a pharmaceutically active substance to or into specific cells.
The invention further encompasses a method for producing a carrier system in the form of protein-based nanoparticles for the cell-specific enrichment of at least one pharmaceutically active substance which comprises the following steps:
With the method according to the invention, the use of gelatine and/or serum albumin, especially serum albumin of human origin, is especially preferred.
Preferably, desolvation is carried out by stirring and the addition of a water-miscible non-solvent for proteins, or by salting-out. The water-miscible non-solvent for proteins is preferably selected from the group consisting of ethanol, methanol, isopropanol and acetone.
To stabilise the nanoparticles, thermal processes or bifunctional aldehydes, especially glutaraldehyde or formaldehyde, are used with preference.
As the thiol group-modifying agent, preferably a substance is used which is selected from the group consisting of 2-iminothiolane, a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and cysteine, or a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and cystaminium dichloride as well as dithiotreitol.
As the bifunctional spacer molecule, preferably a substance is used that is selected from the group consisting of m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester, sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate, sulfosuccinimidyl-2-[m-azido-o-nitrobenzamido]-ethyl-1,3′dithiopropionate, dimethyl-3,3′-dithiobispropionimidate-dihydrochloride and 3,3′-dithiobis[sulfosuccinimidyl propionate].
To prepare protein nanoparticles, 500 mg gelatine A was dissolved in 10.0 ml purified water while heating, and precipitated to a sediment by adding 10.0 ml acetone. The precipitated gelatine was separated, redissolved in 10.0 ml water while heating, and the pH value of the solution was adjusted to pH 2.5. Nanoparticles were obtained from this solution by dropwise addition of 30 ml acetone (desolvation process).
The nanoparticles were stabilised by adding 625 μl glutaraldehyde 8% and stirring over night. The nanoparticles were purified in aliquots of 2.0 ml by 5 cycles of centrifugation and redispersion by ultrasound treatment. For thiolation of the particle surface, 2.5 ml of a solution of 30 mg 2-iminothiolane (Traut's reagent) in Tris-buffer pH 8.5 was added to 1.0 ml of nanoparticle suspension (20 mg/ml), and this was stirred for 24 hours. Following the thiolation, the purification as described above was repeated.
The avidin derivative FITC-NeutrAvidin® was coupled with the thiolated nanoparticles via the bifunctional spacer Sulfo-MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester). To activate the avidin derivative, 0.75 mg sulfo-MBS was added to a solution of 2.5 mg FITC-NeutrAvidin® in 500 μl PBS buffer pH 7.0, and this was stirred for 1 hour at room temperature. The separation of unreacted sulfo-MBS from the activated NeutrAvidin® was made by size exclusion chromatography. Those fractions wherein NeutrAvidin® was detected by a spectrophotometric detection at 280 nm were combined, the suspension of the thiolated nanoparticles was added thereto, and this was stirred for 12 hours at room temperature. A further purification of the now covalently FITC-NeutrAvidin®-modified nanoparticles was performed as described above. The supernatants obtained from the particle purification were photometrically examined for unbound NeutrAvidin®, and the portion of covalently bound NeutrAvidin® was calculated therefrom. The functionality of the bound NeutrAvidin®, expressed as the number of the biotin binding sites per avidin molecule, was determined by a titration experiment with biotin-4-fluorescein. It was shown that 2.4 of the 4 biotin binding sites theoretically present in the avidin molecule are also functionally available after the conjugation with the nanoparticles. For loading with the antibodies, 500 μl of the biotinylated antibodies (25 μg/ml) were added to 150 μl of the NeutrAvidin®-modified nanoparticles (20 mg/ml), followed by incubation for 90 minutes at 10° C.
After incubation, the particles were again purified by centrifugation and redispersion. The resultant particle supernatants were examined for unbound antibodies by Western-Blot analysis. It was shown that more than 80% of the antibody employed was present bound to the particle system.
With the aid of the described particle system, cell-specific particle enrichments were found in different cell culture tests in target cells which carried the surface antigen recognised by the antibody. The following cell culture models were used:
Lymphocytic target cells (Jurkat T cells) with the surface antigen CD3.
Nanoparticles were loaded with a biotinylated anti-CD3 antibody.
Human breast cancer cell lines (SK-Br-3-, MCF-7-, BT474 cells) with expression of the HER2 surface antigen)
Nanoparticles were loaded with the approved antibody Trastuzumab (Herceptin®), which had previously been biotinylated.
The cultured cells were incubated with the nanoparticle system in concentrations between 100 and 1000 μg/ml, and after an incubation time of 4 hours unbound nanoparticles were separated by washing the cells. The cells were examined by flow cytometry (FACS) as well as confocal microscopy (CLSM) with regard to nanoparticle absorption.
For the experiments on the cell-specific absorption of the biotinylated-anti-CD3-antibody-modified nanoparticles in lymphocytic cells, Jurkat-T cells were sown in a density of 1×106 cells per well onto a 24-well microtitre plate and cultured in RPMI medium. The medium was supplemented with 10% (vol/vol) fetal calf serum (FCS), 2% L-glutamine and 1% penicillin/streptomycin. The nanoparticles modified with the antibody were incubated with the cells at a concentration of 1000 μg/ml for a period of 4 hours. To prove a specific cellular absorption via the T cell receptor, different control experiments were performed. On the one hand, nanoparticles were used which were loaded with unspecific IgG antibodies instead of the specific anti-CD3 antibodies. Furthermore, the experiments were performed with Jurkat T cells which were preincubated with 2.5 μg free IgG or anti-CD3 antibodies per 1×106 cells for 30 minutes. After this period, the nanoparticles loaded with the anti-CD3 antibody were added. On the other hand, comparative experiments were carried out using MCF-7 cells which did not have the CD3 surface antigen. The cellular absorption was evaluated qualitatively by confocal microscopy as well as quantitatively by flow cytometry.
For the experiments on the cell-specific absorption of the biotinylated-anti-HER2-antibody-modified nanoparticles in breast cancer cells, HER2-overexpressing cells (BT474 and SK-Br-3) were sown in a density of 2×105, respectively 1×105, cells per well onto a 24-well microtitre plate and cultured in RPMI medium and McCoy's 5 A, respectively. The medium of the BT474 was supplemented with 20% (vol/vol) fetal calf serum (FCS), 2% L-glutamine, 1% penicillin/streptomycin and 100 U insulin. The medium of the SK-Br-3 was supplemented with 10% (vol/vol) fetal calf serum (FCS), 2% L-glutamine and 1% penicillin/streptomycin. The antibody-modified nanoparticles were incubated with the cells at a concentration of 100 μg/ml for a period of 3 hours.
To prove a specific cellular absorption via the HER2 receptor, different comparison experiments were performed. On the one hand, nanoparticles were used which were not loaded with a specific antibody. On the other hand, the experiments were made with MCF-7 cells (normal BER2 expression). Furthermore, control experiments were carried out with SK-Br-3 cells which were pre-incubated for 30 minutes with 2.5 μg/ml free anti-BER2 antibodies (Trastuzumab) per 2×105 cells. After this period, the nanoparticles loaded with the anti-HER2 antibody were added. The cellular absorption was evaluated qualitatively by confocal microscopy as well as quantitatively by flow cytometry.
Lymphocytic Target Cells (Jurkat T Cells)
It was shown both by FACS and CLSM that nanoparticles were cellularly absorbed which were used in a form modified with the cell-specific anti-CD3 antibody. The cellular absorption could be avoided where the cells were treated with the free specific antibody prior to adding the particles. Pretreatment with free unspecific IgG antibodies, however, did not reveal any influence on particle absorption. Modification of the nanoparticles with an unspecific IgG antibody instead of the specific anti-CD3 antibody likewise did not lead to absorption in the target cells. Control experiments were furthermore performed with breast cancer cells (NCF-7 cells) which did not have the CD3 surface antigen. In these control experiments no absorption of the nanoparticle preparations was observed under any of the selected conditions.
Human Breast Cancer Cell Lines (SK-Br-3-, MCF-7-. BT474 Cells)
The cells which were used showed to a different extent an expression of the HER2 surface antigen, which was used as point of attack for cellular absorption of the antibody-modified nanoparticles. Expression of the cells was determined prior to incubation with the nanoparticles by Western-Blot analysis (Table 1).
Both by FACS as well as CLSM, it could be shown that nanoparticles were cellularly absorbed which were used in the form modified with the cell-specific antibody Trastuzumab (
The results of the aforementioned cell culture experiments clearly show that antibody-modified nanoparticles based on gelatine enable a specific enrichment in the target cells. Under comparable conditions the particle systems are absorbed only in the corresponding target cells, but not in control cells. The preincubations with free specific antibody clearly show that particle absorption takes place via a process of receptor-mediated endocytosis. Thus, the nanoparticulate medicinal agent carrier system which has been developed affords the possibility of transporting medicinal substances specifically to diseased cells, provided that these target cells differ in their surface properties from healthy cells.
With the antibody-modified nanoparticles based on gelatine according to the invention there is provided a well-characterized, particulate carrier system which, by a functional drug targeting ligand carried on the surface of said carrier system, enables a cell-specific absorption and enrichment even of such pharmaceutically active substances as are bound to the carrier system by adsorption, incorporation or by covalent or complex-forming bonds.
What has been described above are preferred aspects of the present invention. It is of course not possible to describe every conceivable combination of components or methodologies for purposes of describing the present invention, but one of ordinary skill in the art will recognize that many further combinations and permutations of the present invention are possible. Accordingly, the present invention is intended to embrace all such alterations, combinations, modifications, and variations that fall within the spirit and scope of the appended claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2004 011 776.4 | Mar 2004 | DE | national |
This application is a National Stage application of International Application No. PCT/EP2005/002185, filed on Mar. 2, 2005, which claims priority of German application number 10 2004 011 776.4, filed on Mar. 9, 2004.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP05/02185 | 3/2/2005 | WO | 00 | 8/24/2006 |
